EVEREST: EVErolimus for Renal Cancer Ensuing Surgical Therapy, A Phase III Study.
The purpose of this study is to see whether treatment with everolimus after surgery for kidney cancer will increase the time without cancer returning. Participants in this study have cancer of the kidney that has been surgically removed. The current standard treatment after surgery is careful monitoring with no immediate treatment. Studies suggest that one way kidney cancer may grow is chemical signaling through a protein named “mTOR”. Everolimus is a drug that stops signaling through mTOR and may therefore stop the growth of kidney cancer. Everolimus is a drug currently approved for the treatment of patients with advanced or metastatic kidney cancer.
Back to Clinical Trials list